SG Americas Securities
OBIO icon

SG Americas Securities’s Orchestra BioMed OBIO Stock Holding History

SG Americas Securities’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,785
Closed -$51K – 3662
2024
Q4 		$51K Buy
12,785
+2,642
+26% +$14.2K ﹤0.01% 2902
2024
Q3 		$52K Buy
+10,143
New +$66.3K ﹤0.01% 3241

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SG Americas Securities's OBIO Position: Q1 2025 in Review

SG Americas Securities sold out of Orchestra BioMed (OBIO) in Q1 2025, closing a stake of 12,785 shares — an estimated $51K sold.

SG Americas Securities first reported a position in OBIO in Q3 2024 and held it in 2 quarters. The position peaked at $52K in Q3 2024. 56 funds tracked by Wall St. Rank hold OBIO as of Q1 2025.

  • SG Americas Securities reported no remaining Orchestra BioMed position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 12,785 Orchestra BioMed shares in Q1 2025, an estimated $51K.
  • SG Americas Securities first reported a position in Orchestra BioMed in Q3 2024 and held it in 2 quarters.
  • SG Americas Securities's Orchestra BioMed position peaked at $52K in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.